Diffuse Alveolar Haemorrhage — Viva Defence

Opening statement (SASPOP, delivered aloud)

"Ms Nguyen is a 46-year-old schoolteacher with new PR3-ANCA granulomatosis with polyangiitis, presenting as a pulmonary-renal syndrome: diffuse alveolar haemorrhage confirmed on serial bronchoalveolar lavage, and dialysis-dependent pauci-immune crescentic glomerulonephritis. Her main problems are: life-threatening but currently controlled alveolar haemorrhage on induction immunosuppression; severe renal failure of uncertain reversibility; the cumulative toxicity of steroids and B-cell depletion; and a relapsing-remitting disease that needs a maintenance and monitoring plan. I would like to consolidate remission, protect her from treatment complications, support her renal recovery or transition, and agree a relapse-surveillance plan with her." [6] [7]

Structured problem list

1. Diffuse alveolar haemorrhage (GPA, PR3-ANCA) — confirmed by progressively bloodier serial BAL aliquots; the most dangerous AAV lung manifestation, marking a subgroup with high early mortality and relapse burden [7] [8].
2. Dialysis-dependent crescentic GN — pauci-immune on biopsy; renal recovery over the first 3–6 months is possible but uncertain, and dialysis planning must proceed in parallel [2].
3. Active upper-airway disease — nasal crusting; risk of subglottic and endobronchial involvement; needs ENT input and surveillance.
4. Immunosuppression burden — pulse steroids then taper, rituximab; PJP prophylaxis, bone protection, vaccination timing and fertility discussion all belong on the list [6].
5. Relapse risk and monitoring — PR3-ANCA and GPA phenotype are the relapse-prone combination; maintenance is mandatory, not optional [4].
6. Psychosocial frame — a 46-year-old teacher facing dialysis and a chronic autoimmune disease; goals of care and return-to-work planning are part of the management.

Integrated management plan

• Induction (already started): pulse methylprednisolone 500–1000 mg IV daily for 3 days completed, then an oral taper — I would use a reduced-dose steroid schedule on the PEXIVAS evidence, which was non-inferior with fewer serious infections — plus rituximab 375 mg/m² weekly for 4 doses, the RAVE-established regimen, chosen over cyclophosphamide for her age, fertility priorities and the relapse-prone PR3 phenotype [1] [3].
• Plasma exchange reasoning: I have NOT given routine plasma exchange. PEXIVAS showed no benefit of apheresis on death or end-stage kidney disease in severe AAV, superseding the MEPEX-era practice; I would reserve it only if her DAH proves refractory to induction, or if she were found double-positive for anti-GBM antibody (checked — negative) [3] [9].
• Renal track: continue dialysis; renal biopsy prognosis discussed; reassess renal function monthly for recovery over 3–6 months; referral for transplant work-up only after sustained remission, typically 6–12 months.
• Protection package: PJP prophylaxis while lymphopenic, proton-pump and bone protection through the taper, hepatitis B/C and HIV screening completed before rituximab, and killed vaccines administered before B-cell depletion where timing allowed [6].
• Maintenance (booked now): rituximab 500 mg every 6 months once remission is achieved — superior to azathioprine in MAINRITSAN, and the guideline-preferred choice for severe PR3-ANCA disease; I would plan at least 18–24 months and reassess [4] [6].
• Relapse surveillance: scheduled review with urinalysis, creatinine, CRP and FBC; ANCA titre trends as an adjunct — a rising titre sharpens my suspicion but does not alone trigger treatment; low threshold for repeat CT and BAL if infiltrates or haemoglobin drift [6] [8].

Probing questions with model answers

"Why rituximab and not cyclophosphamide for her induction?" — "RAVE showed rituximab non-inferior to cyclophosphamide for remission in severe AAV, with a trend to superiority in relapsing disease, and RITUXVAS extended that to patients with renal involvement. She is 46 with fertility considerations and a PR3, relapse-prone phenotype; rituximab spares her the bladder, marrow and gonadal toxicity of cyclophosphamide and aligns induction with the maintenance agent she will receive" [1] [2].

"She was dialysis-dependent with alveolar haemorrhage — the exact MEPEX population. Defend not giving plasma exchange." — "MEPEX, in 2007, showed plasma exchange improved dialysis independence in severe renal vasculitis, and it drove a decade of practice. PEXIVAS, 704 patients with eGFR below 50 or alveolar haemorrhage, found no benefit of plasma exchange on death or end-stage kidney disease, and the alveolar-haemorrhage subgroup signal was not practice-proving. The 2021 ACR/VF guideline therefore recommends against routine apheresis in AAV. My residual indications are refractory life-threatening DAH and double-positive anti-GBM disease — neither applies to her" [3] [9] [6].

"Her BAL grew no organisms, but day 10 she spikes a fever and new infiltrate. Relapse or infection?" — "Both are on the table and I would not guess. I would re-bronch: serial aliquots distinguish re-bleeding from a non-haemorrhagic infiltrate, and cultures plus viral PCR cover the opportunists her immunosuppression invites. Empirically I cover infection while the lavage answers the haemorrhage question — the trap is escalating steroids for 'relapse' in what is actually CMV or bacterial pneumonia" [8].

"How long do you maintain her, and with what?" — "Rituximab 500 mg every 6 months, for at least 18–24 months, individualised to her course. MAINRITSAN showed rituximab maintenance halves major relapse compared with azathioprine after induction, and RITAZAREM confirmed the same superiority in the relapsing population. I re-evaluate at 2 years against her remission durability, B-cell recovery, infection history and her own priorities" [4] [5].

"Her ANCA titre is rising at 9 months but she is well. Treat?" — "No — not on the titre alone. A rising PR3-ANCA increases relapse probability and shortens my review interval, but treatment follows clinical relapse: new organ signs, an active urine sediment, falling haemoglobin or new infiltrates. I would examine her, dip the urine, check creatinine and CRP, and image if anything points anywhere" [6].

"What do you tell her about the kidney?" — "Honest staging: some patients recover enough renal function to leave dialysis in the first 3–6 months on induction therapy, and I will keep looking for that. But she should plan as if dialysis continues — modality education, access planning, and transplant discussion once remission is sustained, usually after 6–12 months of quiescent disease" [2].

Communication points

• Prognostic honesty about the kidney without foreclosing recovery — hope framed by the biopsy and the first months of response [2].
• Fertility and treatment-burden counselling before and after induction — rituximab was chosen partly for this, and she should hear why [1].
• A written relapse-action plan she owns: the symptoms (haemoptysis, new cough, bloody urine, sinus flare) that trigger urgent review rather than waiting for the next appointment [6].